Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 4/20 | 0.47 |
| ▸ | KIF18A | Q8NI77 | 1/20 | 0.47 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | FLT1 | P17948 | 1/20 | 0.40 |
| ▸ | FLT4 | P35916 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14866071 | 0.87 | KIF18A (0.57) | TSHRMAPK1VCAM1KIF18ATXNRD1 | |
| SCHEMBL283668 | 0.82 | TSHR (0.55) | TSHRVCAM1TXNRD1SMN1; SMN2 | |
| SCHEMBL1491788 | 0.81 | TXNRD1 (0.46) | TSHRVCAM1TXNRD1SMN1; SMN2POLB | |
| SCHEMBL2060749 | 0.81 | ATM (0.56) | TSHRVCAM1TXNRD1ALDH1A1LMNA | |
| SCHEMBL2062571 | 0.80 | MAPK1 (0.58) | TSHRMAPK1VCAM1KIF18AMAPT | |
| SCHEMBL6130574 | 0.79 | VCAM1 (0.58) | TSHRMAPK1VCAM1KIF18AMAPT | |
| SCHEMBL3891593 | 0.78 | TXNRD1 (0.43) | TSHRMAPK1VCAM1TXNRD1MAPT | |
| SCHEMBL14866258 | 0.78 | TXNRD1 (0.54) | MAPK1TXNRD1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL3891584 | 0.78 | TXNRD1 (0.43) | TSHRMAPK1VCAM1TXNRD1PKM | |
| SCHEMBL2061146 | 0.78 | MAPT (0.55) | TSHRMAPK1VCAM1TXNRD1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | TSHR 3244/4885MAPK1 972/4885VCAM1 3660/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | TSHR 3244/4885MAPK1 972/4885VCAM1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.